Larger institutional shareholders support Recipharm’s cash offer for Consort Medical and subsequent rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES. Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden (holding 7.4%, 7.1% and 5.1% of the total number of shares in Recipharm, respectively, and together 19.6%), support the cash offer for Consort Medical and have undertaken to fully